## baber up 18

Sheet 1 of 3

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO.	SERIAL NO.:
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	1038-1003 MIS:jb	09/462,816
	APPLICANT: Xiaomao L	i et al
	FILING DATE. April 5, 2000 -	GROUP. -1633  635

## **U.S. PATENT DOCUMENTS**

INITIAL	DOCUMENT NO	DATE	NAME	CLASS	SUBČL.	FILING DATE
DM	5,620,896	April/1997	Herrmann et al	435	320 1	April 20, 1995

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
0	1	McIntosh K., Canock, R.M Respiratory Syncytial Virus (In: Fields B.N, Knipe, DM, editors. Virology. New York: Raven Press: 1990. 1045-1072)			
	2	Heilman, C.A Respiratory Syncytial And Parainfluenza Viruses (J. Infect. Dis. 1990, 161–402 to 406)			
	3	Wertz GW, Sullender WM - Approaches To Immunization Against Respiratory Syncytial Virus (Biotechnology 1992, 20: 151-176)			
	4	Murphy, B. R. et al An Update on Approaches to the Development of Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) Vaccines (Virus Res. 32: 13-36, 1994).			
	5	Levine, S., Kleiber-France, R., and Paradiso, P.R Demonstratoin That Glycoprotein G is The Attachment Protein Of Respiratory Syuncytial Virus (J. Gen. Virol. 69, 2521-2524, 1987)			
	6	Anderson, L.J., Hierholzer, J.C., Tsou, C., Hendry, R.M., Fernie, B.F., Stone, Y. and McIntosh, K Antigenic Characterization Of Respiratory Syncytial Virus Strains With Monoclonal Antibodies (J. Infect. Dis. 151, 626-633, 1985)			
	7	Johnson et al Antigenic Relatedness Between Glycoproteins of Human Respiratory Syncytial Virus Subgroups A and B: Evaluation of the Contributions of F and G Glycoproteins to Immunity (J. Virol 1987, 61: 3163-3166)			
	8	Crowe, J.E Current Approaches To The Development Of Vaccines Against Disease Caused By Respiratory Syncytial Virus (R\$V) And Parainfluenza Virus (PIV) (Vaccine 1995, 13: 415-421)			
	9	Kapıkian, A.Z. et al - An Epidemiologic Study of Altered Clinical Reactivity To Respiratory Syncytial (RS) Virus Infection In Children Previously Vaccinated With An Inactivated RS Virus Vaccine (Am. J. Epidemiol. 89: 405-421, 1969)			
	10	Kim, H.W., et alRespiratory Syncytial Virus Disease In Infants Despite Prior Administration Of antigenic Inactivated Vaccine, (Am. J. Epidemiol. 89: 422-434, 1969)			
Br	11	Murphy, B.R. et al - Dissociation Between Serum Neutralizing and Glycoprotein Antibody Responses Of Infants And Children Who Received Inactivated Respiratory Syncytial Virus Vaccine (J. Clin. Microbiol. 24: 197-202, 1986)			
EXAMINER	BA	DATE CONSIDERED: 3/)2/()			

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if in conformance and not considered. Include copy of this form with next communication with applicant.

<sup>\*</sup> Will follow shortly

Sheet 2 of 3

FORM PTO-1449  U.S. DEPARTMENT OF COMMERC PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE  STATEMENT BY APPLICANT		ATTY. DOCKET NO.: SERIAL NO : 09/462,816		
SIAIEM	ENI BY APPLICANT	APPLICANT : Xiaomao Li	et al	
		FILING DATE: April 5, 2000	GROUP: 1633 \673	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NO	DATE	COUNTRY	CLASS	SUBCL	TRANS	SLATION
n.		DOCUMENT NO. WO 90/11092					YES	NO
BN	16	WC 90/11092	04/Oct/90	CPCT VIPO			162	
BN	17	WO 94/21797	29/Sept/94	PET WIFO				
	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
BY	12	Vaux-Peretz, F. et al - Comparison Of The Ability Of Formalin-Inactivated Respiratory Syncytial Virus, Immunopurified F, G And N Proteins And Cell Lysate To Enhance Pulmonary Changes In Balb/c Mice (Vaccine 10: 113-118, 1992)						
	13	Openshaw, P.J.	- Immunopath	ological Mechanisms   17: 187-201 (1995)				
	14	LIEvo Med 179	3·81-89, 1994).	ung Disease Caused B				
	15	L Resnir Crit Ca	are Med 152.56	Respiratory Syncytial V 3-6, 1995)				
	18	Ulmer et al - Poly	Ulmer et al - Polynucleotide Vaccines (Current Opinion, Invest Drugs, 1993, 2: 983-989)					
	19	Chapman, B.S., Thayer, R.M.; Vincent, K.A. and Haigwood, N.L., - Effect of Intron A From Human Cytomegalovirus (Towne) Immediate-early Gene On Heterologous Expression In Mammalian Cells (Nucl. Acids. Res. 1991, 19: 3979-3986)						
	20	Nabel, G.J. et al Direct Gene Transfer With DNA-Liposome Complexes in Melanorna. Expression, Biologic Activity, And Lack Of Toxicity In Humans (Proc. Natl. Acad. Sci. USA 90: 11207-11311, 1993)						
	21	Tang et al Genetic Immunization Is A Simple Method For Eliciting An Immune Response						
	22	Furth et al Gene Transfer Into Somatic Tissues By Jet Injection (Analytical Biochemistry, 1992,						
	23	Davis et al - Direct Gene Transfer In Skeletal Muscle: Plasmid DNA-based Immunization Against						
	24	Graham, B.S.; Perkins M.D.; Wright, P.F. and Karzon, D.1 - Primary Respiratory Syricyttal Virus						
	25	Du, R.P. et al A Prototype Recombinant Vaccine Against Respiratory Syncytial Virus Allu						
nh	26	Prince, G.A. et al The Pathogenesis Of Respiratory Syncytial Virus Infection In Cotton Rats (Ame. J. Pathol 93: 771-790, 1978)						
	-							
EXAMINER	BA	in to Alterna		DATE CONSIDERED	3/7/109			

<sup>\*</sup>EXAMINER: Initial if reference considered, whither is not citation is in confirmance with MPEP 609; Draw line through citation if in conformance and not considered. Include copy of this form with next communication with applicant.

Sheet 3 of 3

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY, DOCKET NO.:	SERIAL NO
	1038-1003 MIS:jb	09/462,816
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		
	APPLICANT: Xiaomao I	et al
	FILING DATE: April 5, 2000	GROUP: 1633 \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \

## **U.S. PATENT DOCUMENTS**

INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCL.	FILING DATE
				<del> </del>		
				<del></del>		

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
Ph	27	Stott, E. J. et al - Human Respiratory Syncytial Virus Glycoprotein G Expressed From A Recombinant Vaccinia Virus Vector Protects Mice Against Live – Virus Challenge (Journal of Virology, (1986 Nov) 60 (2) 607-13)			
	28	Hsu, K. H. et al Journal of Infectious Diseases, (1992 Oct) 166(4) 769-75			
	29	Stott, E. J. et al - Immune And Histopathological Responses In Animals Vaccinated With Recombinant Vaccinia Viruses That Express Individual Genes of Human Respiratory Syncytial Virus (Journal of Virology, (1987 Dec) 61(12) 3855-61)			
	30	Elango, N et al Resistance To Human Respiratory Syncytial Virus (RSV) Infection Induced By Immunization Of Cotton Rats With A Recombinant Vaccinia Virus Expressing The RSV G Glycoprotein (Proc. Natl Acad Sci. USA, (1986 Mar) 83(6) 1906-10)			
	31	Roberts, S.R. et al -The Membrane-Associated And Secreted Forms Of The Respiratory Syncytial Virus Attachment Glycoprotein G Are Synthesized From Alternative Initiation Codons (Journal of Virology, (1994 Jul) 68(7) 4538-46)			
	32	Nguyen, T. N. et al - Hydrophobicity Engineering To Facilitate Surface Display Of Heterologous Gene Products On Straphylococcus Xylosus (Journal of Biotechnology, (1995 Oct 16) 42(3) 207-19)			
	33	Wathen, M. W. et al - Characteristization Of A Novel Human Respiratory Syncytial Virus Chimeric FG Glycoprotein Expressed Using A Baculovirus Vector (Journal of General Virology, (1989 Oct) 70 (PT 10) 2625-35)			
	34	Schrijver, R. S. et al - Companson Of DNA Application Methods To Reduce BRSV Shedding In Cattle (Vaccine, vol 16, no.2-3, 2 January 1998, page 130-134)			
BN	35	Johnson, T. R. et al - Priming With Secreted Glycoprotein G Of Respiratory Syncytial Virus (RSV) Augments Interleukin-5 Production and Tissue Eosinophilia After RSV Challenge (Journal of Virology, (1998 Apr.) 72(4) 2871-80)			
EXAMINER	BA	DATE CONSIDERED. 3/22/02			

<sup>\*</sup>EXAMINER: Initial if reference consider d, whither it not citation is in conformance with MPEP 509; Draw line through citation if in conformance and nit considered. Include copy of this form with nixtic immunication with applicant.

<sup>\*</sup> Will follow shortly